{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042122","form_type":"8-K","ticker":"APUS","cik":"0001894525","company_name":"Apimeds Pharmaceuticals US, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.398783+00:00","generated_at":"2026-05-22T00:38:38.627152+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apimeds Pharmaceuticals US completes $13.5M IPO; starts trading on NYSE American","bullets":["IPO of 3,375,000 shares at $4.00/share; gross proceeds $13.5M.","Proceeds to fund Phase III knee osteoarthritis trial, MS study, manufacturing, working capital.","Convertible notes of $772,545 converted into 297,133 shares at $2.60/share.","Underwriters granted 45-day option for 506,250 additional shares and warrants for 168,750 shares.","Trading began May 9, 2025 on NYSE American under symbol APUS."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042122","json":"https://secwatch.observer/filing/0001213900-25-042122.json","markdown":"https://secwatch.observer/filing/0001213900-25-042122.md","text":"https://secwatch.observer/filing/0001213900-25-042122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025042122/0001213900-25-042122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894525/000121390025042122/ea0241711-8k_apimeds.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:38:38.627152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}